Selling Canadian supplements in the U.S.: NPNs, FDA requirements and NDI notifications
Turn a Canadian product file into a structured U.S. readiness review before committing to stock or marketplace listings.
Request a U.S. entry reviewWhat should a brand do first?
A Canadian NPN does not establish U.S. compliance. Assess ingredient status, any NDI notification obligation, U.S. claims and labelling, manufacturing controls and import arrangements separately. FDA’s October 2026 guidance provides final recommendations on specific NDI identity and safety information; it is not a blanket product approval process.[1][2]
Who this is for: Canadian supplement brands, licence holders, manufacturers and distributors preparing for U.S. retail, direct-to-consumer or marketplace sales.
Does an NPN let you sell a supplement in the United States?
Treat the Canadian product file as a source of useful documents, not as a transferable U.S. permission. It may already contain formula details, specifications and evidence that can support the assessment. Build a gap register showing what is available, what needs updating and what must be evaluated specifically for the United States.
Assign an owner to each gap. The formulation team may need to obtain ingredient process details, while the commercial team confirms the importer and the label team drafts the U.S. presentation. Keeping these workstreams visible helps avoid discovering a critical issue after stock has been manufactured.
When should you investigate an NDI notification?
FDA describes an NDI as a dietary ingredient not marketed in the United States before October 15, 1994. Whether notification is required needs a review of the ingredient and applicable exemptions, including the relevant food-supply provision. When required, notification is submitted at least 75 days before marketing. Do not treat that interval as a guaranteed clearance date or notification as FDA approval.[2]
What does FDA’s October 2026 guidance cover?
The finalized recommendations address identity information, history of use or other safety evidence, and the basis for concluding that the ingredient will reasonably be expected to be safe. These are specific sections of the broader NDI guidance work.
For project planning, ask whether the available documents describe the actual material and intended use. An ingredient trade name without a clear manufacturing description can leave important gaps. Request a coherent evidence package early enough to evaluate it before committing to a launch date.[1]
Build a dossier that matches the ingredient you actually buy.
The supplier name, ingredient identity, manufacturing process and specifications should connect to the evidence being relied on. A familiar ingredient name is only the start of that assessment.
What should an ingredient readiness file contain?
Use the checklist below as a document request framework. The precise dossier needs depend on the ingredient and intended use. A supplier assertion should lead to a supporting document, not close the assessment by itself.
| File area | Useful questions for the supplier |
|---|---|
| Identity and composition | What defines the ingredient, including relevant constituents and specifications? |
| Manufacturing | Which process steps could affect identity, composition or impurity levels? |
| Analytical support | Are the methods appropriate for the actual material and specification? |
| History and regulatory rationale | What evidence supports the claimed U.S. status or reliance on an existing notification? |
| Safety and exposure | Does the supporting evidence address the intended daily amount, population and duration? |
| Change control | How will the brand be informed about material or process changes? |
Why the Canadian claim cannot simply be copied
FDA’s dietary supplement structure/function framework includes substantiation, a required disclaimer and notification within 30 days after first marketing for applicable claims. Disease-treatment claims raise different regulatory issues. Review the whole presentation, including names, testimonials and online copy, rather than changing only the facts panel.[3]
Who is responsible for manufacturing and import readiness?
FDA’s import guidance identifies applicable U.S. requirements, facility registration and prior notice as part of food import readiness. Separately assess foreign supplier verification responsibilities; dietary supplements can have modified FSVP requirements depending on the circumstances. Do not assume that hiring a customs broker resolves every obligation.[4][5]
A practical U.S. launch sequence
Begin with the exact commercial formula and ingredient suppliers. Resolve ingredient-status questions early, particularly where an NDI assessment may affect timing. Next, build the U.S. claims and label review around the selected product category and intended audience.
In parallel, confirm manufacturing documentation, testing, the importing arrangement and operational responsibilities. Before releasing stock, reconcile the approved label with the formula and supporting records. Make the final checkpoint a documented readiness decision rather than simply the date the designer delivered the artwork.
What to gather before requesting a review
Send what you have and identify what is still being developed. These documents help us define a useful scope and the questions to resolve first.
- Complete formula and current Canadian product licence
- Ingredient specifications, suppliers and manufacturing descriptions
- Evidence supporting U.S. ingredient status and any prior NDI work
- Current labels and proposed U.S. claims, including web listings
- Manufacturing, testing and quality documentation
- Intended importer, facilities, sales channels and launch schedule
Questions brands ask
Does FDA approve dietary supplements through an NDI notification?
An NDI notification is not a general product approval. Evaluate the notification requirement and the wider compliance obligations separately.
Does every ingredient need a new notification?
No. Ingredient status, available evidence and applicable exemptions need to be assessed. Avoid a blanket answer based only on a familiar ingredient name.
Can our supplier’s existing NDI work cover our product?
Investigate whether the actual ingredient and conditions of use match what can legitimately be relied upon. Ask for the supporting documentation rather than relying only on a reference number.
Is an FDA-registered facility enough?
Facility registration does not by itself establish finished-product compliance. Ingredient, label, manufacturing and import requirements still need review.
Can we launch on a marketplace while the review continues?
A marketplace listing is not a substitute for compliance. Resolve the relevant launch requirements before introducing the product.
Turn the next decision into a clear plan.
Kompete can compare your current Canadian product package with the questions that need to be resolved for U.S. entry and organize a practical action plan.
Request a U.S. entry reviewExplore this serviceinfo@kompeteconsulting.com
Related insights
Sources and scope
Sources checked October 22, 2026. Regulatory requirements and guidance can change. The checklists, examples and development workflows are Kompete’s practical planning suggestions; product-specific decisions require review of the actual formula, intended use and documentation.